Hemispherx Biopharma, Inc. (HEB) stock is breaking out today, $2.92 Up 17.50%, one day before a conference call to update shareholders on influenza prevention. HEB is breaking out above the previous June 2009 high of $2.85 which is bullish.Ampligen: HEB is also waiting for an FDA decision on their CFS drug Ampligen. Investors and Traders could be getting in with anticipation that we will hear an positive update on Ampligen. After seeing what happened to Human Genome Sciences Inc. (HGSI), an FDA approval for Ampligen could be explosive for HEB.
Update - 7/22/09 - " Still Waiting on Response from FDA on Ampligen "
HEMISPHERX BIOPHARMA TO PROVIDE UPDATE ON GLOBAL PANDEMIC INFLUENZA PREVENTION / TREATMENT INITIATIVES
Philadelphia, PA, Monday, July 20, 2009: Hemispherx Biopharma (NYSE AMEX: HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Background information may be sourced at Wall Street Journal, July 18/19, 2009, p. A3.
Hemispherx’s Medical Director, CEO, and the Managing Director of the Sage Group, a health care consulting firm retained by Hemispherx, will participate. Investigational products and protocols to be discussed will include Hemispherx’s Ampligen® (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery. Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
